John M. Goldman
Impact in
- Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 455
- Chronic Myeloid Leukemia Treatments 337
- Acute Myeloid Leukemia Research 131
- Hematopoietic Stem Cell Transplantation 117
- Genetics 283
- Chronic Lymphocytic Leukemia Research 239
- Co-authors
- Junia V. Melo (34 shared papers)Michael W. Deininger (19 shared papers)Jane Apperley (129 shared papers)Richard Szydlo (67 shared papers)Nicholas C.P. Cross (53 shared papers)Andreas Hochhaus (31 shared papers)Timothy P. Hughes (26 shared papers)Jaspal Kaeda (39 shared papers)
- Journals
- Blood (141 papers)British Journal of Haematology (80 papers)The Lancet (23 papers)Leukemia Research (15 papers)Leukemia (15 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
John M. Goldman
561 papers receiving 41.6k citations
John M. Goldman's Hit Papers
Peers
Comparison fields: 5 of 183
- Hematology 32.4k
- Genetics 18.8k
- Rheumatology 11.3k
- Oncology 6.4k
- Immunology 4.6k
Countries citing papers authored by John M. Goldman
This map shows the geographic impact of John M. Goldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Goldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Goldman more than expected).
Fields of papers citing papers by John M. Goldman
This network shows the impact of papers produced by John M. Goldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Goldman. The network helps show where John M. Goldman may publish in the future.
Co-authors
The 25 scholars most cited alongside John M. Goldman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 569 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Hit paper breakdown → | 2003 | 2905 |
| 2 | Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia Hit paper breakdown → | 2006 | 2851 |
| 3 | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 Hit paper breakdown → | 2013 | 1614 |
| 4 | The molecular biology of chronic myeloid leukemia Hit paper breakdown → | 2000 | 1318 |
| 5 | Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet Hit paper breakdown → | 2009 | 1050 |
| 6 | Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia Hit paper breakdown → | 2003 | 1022 |
| 7 | A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2013 | 940 |
| 8 | Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment Hit paper breakdown → | 2003 | 767 |
| 9 | Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib Hit paper breakdown → | 2010 | 749 |
| 10 | Bone Marrow Transplantation for Chronic Myelogenous Leukemia in Chronic Phase Hit paper breakdown → | 1988 | 740 |
| 11 | Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Hit paper breakdown → | 2009 | 710 |
| 12 | Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Hit paper breakdown → | 2000 | 657 |
| 13 | 1997 | 530 | |
| 14 | 2002 | 528 | |
| 15 | International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Hit paper breakdown → | 2009 | 502 |
| 16 | 2008 | 479 | |
| 17 | 2003 | 450 | |
| 18 | 2000 | 433 | |
| 19 | 2005 | 417 | |
| 20 | 1997 | 409 |
About John M. Goldman
John M. Goldman is a scholar working on Hematology, Genetics, Rheumatology, Immunology and Oncology, having authored 569 papers that have together received 43.8k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (337 papers), Chronic Lymphocytic Leukemia Research (239 papers), Acute Myeloid Leukemia Research (131 papers), Eosinophilic Disorders and Syndromes (123 papers), Hematopoietic Stem Cell Transplantation (117 papers), Acute Lymphoblastic Leukemia research (68 papers), Lymphoma Diagnosis and Treatment (34 papers) and T-cell and B-cell Immunology (30 papers). The work is most often cited by research in Hematology (32.4k citations), Genetics (18.8k citations), Rheumatology (11.3k citations), Oncology (6.4k citations) and Immunology (4.6k citations). John M. Goldman has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Junia V. Melo, Michael W. Deininger, Jane Apperley, Richard Szydlo, Nicholas C.P. Cross, Andreas Hochhaus, Timothy P. Hughes, Jaspal Kaeda, Eduardo Olavarría and Jerald P. Radich. Their work appears in journals such as Blood, British Journal of Haematology, The Lancet, Leukemia Research and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.